Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference
Aileron Therapeutics, Inc. (ALRN)
Last aileron therapeutics, inc. earnings: 11/7 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.aileronrx.com
Company Research
Source: GlobeNewswire
Nonclinical research results show that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells and enhanced the anti-cancer activity of chemotherapy ALRN-6924 could enable a precision-medicine strategy to prevent the toxic side effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer WATERTOWN, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, presented new data at the 2019 AACR-NCI-EORTC Conference from nonclinical studies in which ALRN-6924, a dual inhibitor of MDM2 and MDMX, prevented chemotherapy-related toxicities in cellular studies and mouse models of cancer without limiting – and even enhancing – anti-cancer efficacy. “Chemotherapy is widely used to treat – and often cure – millions of cancer patients each year, but chemotherapy is toxic and commonly causes severe or life-threatening si
Show less
Read more
Impact Snapshot
Event Time:
ALRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALRN alerts
High impacting Aileron Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALRN
News
- Aileron Therapeutics GAAP EPS of -$0.27 misses by $0.02 [Seeking Alpha]Seeking Alpha
- Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
- Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsPR Newswire
- Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis [Yahoo! Finance]Yahoo! Finance
- Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)PR Newswire
ALRN
Sec Filings
- 12/9/24 - Form 4
- 12/6/24 - Form 4
- 12/6/24 - Form 4
- ALRN's page on the SEC website